Discovery of highly immunogenic spleen-resident FCGR3⁺CD103⁺ cDC1s differentiated by IL-33-primed ST2⁺ basophils.

ABSTRACT: Recombinant interleukin-33 (IL-33) inhibits tumor growth, but the detailed immunological mechanism is still unknown. IL-33-mediated tumor suppression did not occur in Batf3^-/- mice, indicating that conventional type 1 dendritic cells (cDC1s) play a key role in IL-33-mediated antitumor immunity. A population of CD103⁺ cDC1s, which were barely detectable in the spleens of normal mice, increased significantly in the spleens of IL-33-treated mice. The newly emerged splenic CD103⁺ cDC1s were distinct from conventional splenic cDC1s based on their spleen residency, robust effector T-cell priming ability, and surface expression of FCGR3. DCs and DC precursors did not express Suppressor of Tumorigenicity 2 (ST2). However, recombinant IL-33 induced spleen-resident F

SUBMITTER: Kang MH 

PROVIDER: S-EPMC10310784 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature